Clinical trials
Kidney Transplant Rejection clinical trials
Below are recruiting kidney transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT06351488Recruiting
Detecting kidney DNA to spot organ rejection early
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
ParisAges 18 years+ - NCT07060716Recruiting
Blood test to monitor kidney transplant health
This study is testing a blood test that looks for tiny pieces of the donor's DNA in your blood to check how your new kidney is doing. It may help doctors monitor your transplant and spot problems early, possibly without needing a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06910527Recruiting
Testing blood and urine for kidney rejection signs
This study is for people with a kidney transplant who are in the hospital for a biopsy because their doctor suspects rejection. Researchers want to see if a simple blood or urine test can detect rejection, which might make future biopsies less necessary.
RouenAges 18 years+ - NCT06025240Recruiting
Better antibody monitoring after kidney transplant
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
Liverpool, MerseysideAges 18 years+ - NCT05600634Recruiting
Monitoring skin graft to spot rejection after kidney transplant
This study follows people after a kidney transplant to see if a small skin graft can help detect early signs of acute rejection. It may help your care team notice rejection sooner and adjust treatment earlier.
Xi'an, ShannxiAges 18–60 - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT05084768Recruiting
Test blood markers to predict kidney transplant rejection
This study looks at special blood tests to help predict when kidney transplant rejection might happen. If the markers work, they could help doctors catch rejection earlier and adjust treatment sooner.
Loma Linda, CaliforniaAges 18 years+ - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT03955172Recruiting
Test of everolimus to reduce transplant rejection
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
LyonAges 18 years+ - NCT07134491Recruiting
B Cells in Kidney Transplant Rejection Study
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
ParisAges 18 years+ - NCT06474273RecruitingPhase 3
Treating T-cell rejection after kidney transplant
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Lambton, New South WalesAges 2 years+ - NCT06342128Recruiting
Molecular study of inflammation in kidney transplants
This study looks at molecular changes in kidney transplants that have microvascular inflammation (a type of injury). It aims to better understand why some transplants get this inflammation, which could lead to better treatments.
ParisAges 18–100 - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT06314230Recruiting
Genomics of chronic kidney transplant failure study
This study looks at how genes affect long-term kidney transplant health. It aims to understand why some transplanted kidneys fail over time, and may help personalize care for transplant recipients.
Westmead, New South WalesAges 18–75 - NCT07663669Recruiting
Photopheresis for antibody-mediated rejection in kidney transplant
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
BesançonAges 18 years+ - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT07275541Recruiting
Platelet test for early kidney rejection diagnosis
This study tests whether a simple blood test that looks at platelet behavior can help doctors diagnose acute rejection after a kidney transplant. Early detection of rejection may lead to faster treatment and better outcomes.
MartinAges 18 years+ - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Birmingham, AlabamaAges 18–70 - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Kidney Transplant Rejection trials by city
Studies with a site in or near these metro areas.
Kidney Transplant Rejection trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for kidney transplant rejection?
- Yes. Clin2 currently lists 79 recruiting kidney transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.